Einloggen

Thematische Bibliographien / IMMUNOPHARMACOLOGICAL

Inhaltsverzeichnis

Zeitschriftenartikel
Dissertationen
Buchteile

Auswahl der wissenschaftlichen Literatur zum Thema „IMMUNOPHARMACOLOGICAL“

Autor: Grafiati

Veröffentlicht am 18. Mai 2024

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "IMMUNOPHARMACOLOGICAL" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Zeitschriftenartikel zum Thema "IMMUNOPHARMACOLOGICAL"

1

Ielpo, M. T. L., A. Basile, R. Miranda, V. Moscatiello, C. Nappo, S. Sorbo, E. Laghi, M. M. Ricciardi, L. Ricciardi und M. L. Vuotto. „Immunopharmacological properties of flavonoids“. Fitoterapia 71 (August 2000): S101—S109. http://dx.doi.org/10.1016/s0367-326x(00)00184-2.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

Kovalenko, L. P., E. V. Shipaeva, S. V. Alekseeva, A. V. Pronin, A. D. Durnev, T. A. Gudasheva, R. U. Ostrovskaja und S. B. Seredenin. „Immunopharmacological properties of noopept“. Bulletin of Experimental Biology and Medicine 144, Nr. 1 (Juli 2007): 49–52. http://dx.doi.org/10.1007/s10517-007-0251-3.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

Zhang, Jianmei, Stephanie Triseptya Hunto, Yoonyong Yang, Jongsung Lee und Jae Youl Cho. „Tabebuia impetiginosa: A Comprehensive Review on Traditional Uses, Phytochemistry, and Immunopharmacological Properties“. Molecules 25, Nr. 18 (18.09.2020): 4294. http://dx.doi.org/10.3390/molecules25184294.

Der volle Inhalt der Quelle

Annotation:

Tabebuia impetiginosa, a plant native to the Amazon rainforest and other parts of Latin America, is traditionally used for treating fever, malaria, bacterial and fungal infections, and skin diseases. Additionally, several categories of phytochemicals and extracts isolated from T. impetiginosa have been studied via various models and displayed pharmacological activities. This review aims to uncover and summarize the research concerning T. impetiginosa, particularly its traditional uses, phytochemistry, and immunopharmacological activity, as well as to provide guidance for future research. A comprehensive search of the published literature was conducted to locate original publications pertaining to T. impetiginosa up to June 2020. The main inquiry used the following keywords in various combinations in titles and abstracts: T. impetiginosa, Taheebo, traditional uses, phytochemistry, immunopharmacological, anti-inflammatory activity. Immunopharmacological activity described in this paper includes its anti-inflammatory, anti-allergic, anti-autoimmune, and anti-cancer properties. Particularly, T. impetiginosa has a strong effect on anti-inflammatory activity. This paper also describes the target pathway underlying how T. impetiginosa inhibits the inflammatory response. The need for further investigation to identify other pharmacological activities as well as the exact target proteins of T. impetiginosa was also highlighted. T. impetiginosa may provide a new strategy for prevention and treatment of many immunological disorders that foster extensive research to identify potential anti-inflammatory and immunomodulatory compounds and fractions as well as to explore the underlying mechanisms of this herb. Further scientific evidence is required for clinical trials on its immunopharmacological effects and safety.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

4

Kawakita, Takuya. „Immunopharmacological effects of Kampo medicines“. Folia Pharmacologica Japonica 132, Nr. 5 (2008): 276–79. http://dx.doi.org/10.1254/fpj.132.276.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

5

Borriello, Francesco, Francescopaolo Granata, Gilda Varricchi, Arturo Genovese, Massimo Triggiani und Gianni Marone. „Immunopharmacological modulation of mast cells“. Current Opinion in Pharmacology 17 (August 2014): 45–57. http://dx.doi.org/10.1016/j.coph.2014.07.002.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

6

Simbirtsev, A. S. „Immunopharmacological aspects of the cytokine system“. Bulletin of Siberian Medicine 18, Nr. 1 (16.05.2019): 84–95. http://dx.doi.org/10.20538/1682-0363-2019-1-84-95.

Der volle Inhalt der Quelle

Annotation:

Cytokines represent a unique family of endogenous polypeptide mediators of intercellular interaction. From an immunopharmacological point of view cytokines can be marked out as a new, separate immunoregulatory molecule system and have some common biochemical properties and pleiotropic type of biological activity. In the cytokine regulatory system both reduction and elevation of cytokine levels can cause pathology. Several endogenous systems exist to control cytokine elevation and prevent tissue pathology. When synthesized simultaneously, cytokines form a cytokine chain. Deletion of any unit of this chain leads to the break in the formation of immunopathology. Cytokines as therapeutic preparations have evident advantages but also some limitations such as pharmacokinetics with short circulation period, adverse effects due to pleiotropic mode of action, and injectable drug forms. Rational design for clinical cytokine application could be linked with the development of prolonged and local drug forms or personalized cytokine therapy.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

7

Farjam, Mojtaba, Guang-Xian Zhang, Bogoljub Ciric und Abdolmohamad Rostami. „Emerging immunopharmacological targets in multiple sclerosis“. Journal of the Neurological Sciences 358, Nr. 1-2 (November 2015): 22–30. http://dx.doi.org/10.1016/j.jns.2015.09.346.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

8

Kouttab, N., M. Prada und B. Brunetti. „Immunopharmacological profile of two synthetic tripeptides“. International Journal of Immunopharmacology 10 (Januar 1988): 126. http://dx.doi.org/10.1016/0192-0561(88)90472-9.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

9

IVANOVSKA, NINA, STEFAN PHILIPOV und PEPA GEORGIEVA. „IMMUNOPHARMACOLOGICAL ACTIVITY OF APORPHINOID ALKALOID OXOGLAUCINE“. Pharmacological Research 35, Nr. 4 (April 1997): 267–72. http://dx.doi.org/10.1006/phrs.1996.9994.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

10

Kirchhof, Julia, Liubov Petrakova, Alexandra Brinkhoff, Sven Benson, Justine Schmidt, Maike Unteroberdörster, Benjamin Wilde, Ted J. Kaptchuk, Oliver Witzke und Manfred Schedlowski. „Learned immunosuppressive placebo responses in renal transplant patients“. Proceedings of the National Academy of Sciences 115, Nr. 16 (02.04.2018): 4223–27. http://dx.doi.org/10.1073/pnas.1720548115.

Der volle Inhalt der Quelle

Annotation:

Patients after organ transplantation or with chronic, inflammatory autoimmune diseases require lifelong treatment with immunosuppressive drugs, which have toxic adverse effects. Recent insight into the neurobiology of placebo responses shows that associative conditioning procedures can be employed as placebo-induced dose reduction strategies in an immunopharmacological regimen. However, it is unclear whether learned immune responses can be produced in patient populations already receiving an immunosuppressive regimen. Thus, 30 renal transplant patients underwent a taste-immune conditioning paradigm, in which immunosuppressive drugs (unconditioned stimulus) were paired with a gustatory stimulus [conditioned stimulus (CS)] during the learning phase. During evocation phase, after patients were reexposed to the CS, T cell proliferative capacity was significantly reduced in comparison with the baseline kinetics of T cell functions under routine drug intake (ƞp2 = 0.34). These data demonstrate, proof-of-concept, that learned immunosuppressive placebo responses can be used as a supportive, placebo-based, dose-reduction strategy to improve treatment efficacy in an ongoing immunopharmacological regimen.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Mehr Quellen

Dissertationen zum Thema "IMMUNOPHARMACOLOGICAL"

1

Roy, Subhrajyoti. „Immunopharmacological Investigation of an Edible Fern, Diplazium esculentum (Koenig ex Retz) sw.., Available in North Bengal Region“. Thesis, University of North Bengal, 2016. http://hdl.handle.net/123456789/2480.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

Okayama, Yoshimichi. „Immunopharmacological studies on human mast cells and basophils“. Thesis, University of Southampton, 1994. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.296403.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

Govindappa, Karthik. „Immunopharmacological consequences of immune responses to therapeutic interferon beta“. Thesis, University of Liverpool, 2013. http://livrepository.liverpool.ac.uk/15173/.

Der volle Inhalt der Quelle

Annotation:

Protein therapeutics or biologics represent 30 % of current licensed pharmaceutical products. In general, biologics offer superior safety profiles compared to small molecules. However, significant clinical concerns have emerged in terms of development of anti-drug antibodies (ADAs), a phenomenon that is covered under the term, immunogenicity. Anti-drug antibodies can alter pharmacokinetics, reduce efficacy of the therapeutic and also can in some cases induce allergic reactions. Human recombinant interferon beta (IFN-β) is a biologic used for the treatment of multiple sclerosis (MS) – a chronic, inflammatory and demyelinating disease of the central nervous system. Long-term treatment with IFN-β has been shown to lead to the development of anti-IFN-β antibodies that can cause total loss or reduced efficacy. Anti-drug antibodies can be non-neutralising (N-NAb) and neutralising (NAb) depending on the site to which they bind. This study aimed to conduct a systematic review to determine factors affecting the formation of neutralising antibodies against three different formulations of IFN-β Avonex™, Rebif™ and Betaseron/Betaferon™. Findings from the systematic review highlight the relative differences in immunogenicity risk of different IFN-β formulations Avonex™, Rebif ™ and Betaseron/Betaferon™ with Avonex™ having the lowest risk, Rebif™ has moderate risk and Betaseron/Betaferon™ has high risk. Characterising the immunoglobulin profile of the IFN-β ADAs from the plasma of ADA positive MS patients revealed that IFN-β ADAs are predominantly of the IgG1 and IgG4 subclass. We also characterised the neutralising potential of the major ADA IgG4 subclass using a IFN-β bioactivity assay and show that IgG4 antibodies may likely contribute to the neutralisation activity. The potential of the neutralising ADAs to cross-react with endogenous IFN-β was investigated using an in vitro bioactivity assay. Findings from this set of experiments revealed varying degrees of neutralisation of endogenous IFN-β. We next explored the potential immunological consequence of ADA with regards to formation of immune complexes and activation of complement. The interaction of ADAs with the biologic can result in formation of immune complex. Immune complexes can activate the complement system. The data revealed IFN-β ADAs can form immune complexes with IFN-β and therefore activate complement. We also attempted to identify IFN-β linear epitopes that the ADAs had the ability to bind. However, a combination of multipin peptide technology and in vitro peptide competitive binding assay failed to reveal a definitive linear epitope although there was some evidence for the existence of potential linear epitopes. We also examined the involvement of T helper cells and T regulatory cells (Tregs) in ADA development. The data revealed no significant differences in the frequency of Tregs among IFN-β ADAs positive, negative and healthy donors. Attempts were also made to identify T helper epitopes within IFN-β that could potentially drive immunogenicity. Using T-cell epitope prediction tools (IEDB-AR and ProPred) and T-cell functional assays we identified an immunogenic sequence of 36 amino acids within IFN-β (position 130-166). Our data revealed that one IFN-β peptide within this sequence is a potential T-cell immunogenic epitope. In addition we identified a possible association of one IFN-β derived peptide with the DRB1*1501HLA haplotype. In summary, the results presented in this thesis have provided essential information on subclass profile of IFN-β ADAs, the possible involvement of T helper cells and potential antibody epitopes within IFN-β. Future studies should be aimed at providing greater detail on the evolution of the ADA response and test strategies to remove immunogenic determinants from IFN-β.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

4

Dey, Priyankar. „Immunopharmacological investigations of the herb nerium indicum miller (apocynaceae)“. Thesis, University of North Bengal, 2015. http://hdl.handle.net/123456789/1861.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

5

Boylan, M. T. „Immunopharmacological aspects of methylprednisolone and interferon-beta therapies in multiple sclerosis“. Thesis, Queen's University Belfast, 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.269028.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

6

Dutta, Somit. „Immunopharmacological evaluation of leaf extract of an ethnomedicinal herb, croton bonplandianus baill (euphorbiaceae)“. Thesis, University of North Bengal, 2018. http://hdl.handle.net/123456789/2658.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Buchteile zum Thema "IMMUNOPHARMACOLOGICAL"

1

Drews, Jürgen. „Antibodies as Immunopharmacological Agents“. In Immunopharmacology, 92–128. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-75561-3_3.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

Archer, Clive B. „Immunopharmacological Mechanisms in Atopic Dermatitis“. In Harper's Textbook of Pediatric Dermatology, 25.1–25.13. Oxford, UK: Wiley-Blackwell, 2011. http://dx.doi.org/10.1002/9781444345384.ch25.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

Gilman, Steven C., und Alan J. Lewis. „Immunopharmacological Approaches to Drug Development“. In Drug Discovery and Development, 227–56. Totowa, NJ: Humana Press, 1987. http://dx.doi.org/10.1007/978-1-4612-4828-6_9.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

4

Mašek, K. „Immunopharmacological Aspects of Mental Disorders“. In New Concepts in Depression, 306–19. London: Macmillan Education UK, 1988. http://dx.doi.org/10.1007/978-1-349-09506-3_28.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

5

Østensen, Monika. „Immunopharmacological Treatment during Pregnancy and Lactation“. In Immunopharmacology in Autoimmune Diseases and Transplantation, 245–60. Boston, MA: Springer US, 1992. http://dx.doi.org/10.1007/978-1-4899-1167-4_19.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

6

Zídek, Z., K. Mašek, M. Svobodová, K. Šůla, K. Nouza und J. Müller. „Some Immunopharmacological Properties of Adamantylamide Dipeptide (AdDP)“. In Immunotherapeutic Prospects of Infectious Diseases, 363–66. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-76120-1_48.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

7

Lien, Eric J., Arima Das und Linda L. Lien. „Immunopharmacological and biochemical bases of Chinese herbal medicine“. In Progress in Drug Research/Fortschritte der Arzneimittelforschung/Progrès des recherches pharmaceutiques, 263–80. Basel: Birkhäuser Basel, 1996. http://dx.doi.org/10.1007/978-3-0348-8996-4_7.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

8

Singh, Vijendra K., und H. Hugh Fudenberg. „Immunopharmacological approach to the study of chronic brain disorders“. In Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques, 345–63. Basel: Birkhäuser Basel, 1986. http://dx.doi.org/10.1007/978-3-0348-9311-4_10.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

9

Chakraborty, Pritha, Moytrey Chatterjee, Ankita Chakraborty, Somrita Padma und Suprabhat Mukherjee. „Phytochemicals as Modulators of Toll-Like Receptors: An Immunopharmacological Perspective“. In Medicinal Plants and Antimicrobial Therapies, 49–83. Singapore: Springer Nature Singapore, 2024. http://dx.doi.org/10.1007/978-981-99-7261-6_3.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

10

Ladel, C. H., H. Püschner und U. Bamberger. „The SCID Mouse and its use for Immunopharmacological and Immunotoxicological Investigations“. In Archives of Toxicology, 472–87. Berlin, Heidelberg: Springer Berlin Heidelberg, 1995. http://dx.doi.org/10.1007/978-3-642-79451-3_41.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!